Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001928943 | SCV002200269 | benign | Ornithine carbamoyltransferase deficiency | 2024-12-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV001928943 | SCV004824440 | uncertain significance | Ornithine carbamoyltransferase deficiency | 2023-06-26 | criteria provided, single submitter | clinical testing | This missense variant replaces glycine with aspartic acid at codon 241 of the OTC protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with OTC-related disorders in the literature. This variant has been identified in 1/183224 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004656745 | SCV005155181 | uncertain significance | Inborn genetic diseases | 2024-05-09 | criteria provided, single submitter | clinical testing | The c.722G>A (p.G241D) alteration is located in exon 8 (coding exon 8) of the OTC gene. This alteration results from a G to A substitution at nucleotide position 722, causing the glycine (G) at amino acid position 241 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |